U.S. stock futures pointed higher after a technology-led selloff, with Dow Jones futures up 0.45%, S&P 500 futures gaining 0.31% and Nasdaq 100 futures rising 0.28%. Moderna shares surged more than 94% in premarket trading after an interim late-stage trial showed its melanoma vaccine, combined with Merck's Keytruda, met both primary goals; Merck rose 6.6%, while Novavax and BioNTech also gained. Target raised its annual sales forecast, but Lowe's cut its comparable-sales outlook to no growth as consumers remained cautious. Bond markets remained under pressure, with the 30-year Treasury yield at 5.197% near its highest level since 2007, while investors awaited Federal Reserve meeting minutes and monitored Middle East tensions. Other corporate developments included Marvell's $12.18 billion Google warrant agreement, Estee Lauder's upbeat profit forecast, SK hynix's planned 40 trillion-won share buyback, Cerebras' CS-4 AI system, Nebius' planned $4.5 billion convertible senior-notes issue, memory-price forecasts from Morgan Stanley and a Goldman Sachs projection that the space economy could reach $1.8 trillion by 2035.